Abstract Background: Hepatitis D virus infection may worsen HBV infection and about 5 % of HBV infected individuals may be infected with HDV infection as these viruses
Introduction
In Africa, the prevalence of both HIV and HBV infection is high (O'Shea, 2010; UNAIDS, 2016). In Nigeria, the prevalence of HIV infection and HBV infection is 3.4 % and 13.6 % respectively (UNAIDS, 2015; Musa et al, 2015) . The morbidity and mortality of liver diseases due to HBV infection increase in the setting of HIV/HBV co-infection, as a result of negative effect of HIV infection on the natural course of HBV infection (Thio, 2009 ).
Tropical and sub-Tropical regions have the highest prevalence of HDV infection and about 5 % of HBV infected patients may be affected by HDV infection (Sultanik and Pol, 2016) . Hepatitis D Virus (HDV) infection occurs simultaneously with HBV infection or as super-infection of HBV infection (Greenwood, 1997; Sultanik and Pol, 2016) . Both HBV and HDV infections may persist following HDV super-infection and the severity of HBV infection increases with HDV co-infection (Greenwood, 1997) .
Fulminant hepatitis is more common in HDV/HBV co-infection than in HBV infection alone, HBV vaccine prevents HDV infection and HDV prognosis in the setting of HIV infection is open to doubt (Sultanik and Pol, 2016) . Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) are some of the tests that measure liver cell integrity. Autoimmune manifestations, hepatocellular carcinoma and liver failure may follow as the complications of HDV infection (http: //www.emedicine.medscape.com/article/178038-overview). ISSN: 2520-3134 New drugs such as prenylation and myrcludex are active against HBV and HDV and are therefore promising for the treatment of HBV/HDV co-infection (Sultanik and Pol, 2016) .
The screening of HDV infection is not a common practice in many health institutions and studies on HDV infection is limited in resource limited countries. Therefore, this study aimed at determination of HDV infection among HIV and HBV co-infected patients.
Methods
A cross sectional study was adopted in which 180 treatment-naïve HIV study participants were recruited into the study between March 2014 and October 2015. The study participants attended HIV clinic at Usmanu Danfodiyo University Teaching Hospital (UDUTH) Sokoto and Specialist Hospital Sokoto and approval for the study was obtained from the ethical committee of UDUTH Sokoto and Ministry of health Sokoto. Patients that were vaccinated for HBV infection were excluded from the study.
Data about the study subjects were obtained by employing interviewer administered technique using a questionnaire. Blood samples were obtained from the study participants after getting their informed consent and were screened for HBs Ag with HBs Ag ELISA kit (Fortress Diagnostic UK). Patients that were positive for HBs Ag were further screened for anti HDV with HDV IgG ELISA Kit (Perfemed South San Francisco the United States).
Patients who tested positive to anti HDV were further screened for HBe Ag using HBe Ag ELISA kit (DRG International Inc, USA), assessed for CD4+ T lymphocyte counts (Cyflow counter analyzer, PARTEC, Germany) and AST as well as ALT levels using Agappe Kit (Agappe Diagnostics, Switzerland; normal ranges of up to 46 IU/L and 49 IU/L respectively). These values were compared among variables of interest.
Statistical Package for Social Sciences (SPSS Version 20) was used for the data analysis. Student's ttest and Chi-square test were applied for the test of significance. Level of significance was set at p ≤ 0.05.
Results
Of the 37 HIV infected study participants that were positive for HBs Ag, 4(10.8 %) were positive for anti HDV and therefore infected with HDV infection. Their age was 32 ± 10 (Mean ± SD) and comprises of 21(56.8 %) and 16(43.2 %) males and females respectively. (Table 1 ) Table 1 . Demographic data and prevalence of anti HDV among HIV/HBV co-infected study participants
Variable
HIV/HBV co-infection (n=37) Anti HDV n (%) 4(10. There was no statistically significant age group and sex difference in the prevalence of HDV infection among the HIV/HBV co-infected study participants, though numerically higher among Females, 2(12.5 %) against 2(9.5 %) in Males (P≤ 0.587) and higher among age group 41-50, 1(14.3 %) compared to other age groups (P ≤ 0.671). Subjects with history of multiple sexual partners (MSP), blood transfusion and needle sharing had higher percentage of HDV infection compared to subjects with negative history of such variables even though there was no statistical significance (13.8 % Vs 0.0 %, P≤ 0.557), (33.3 % Vs 8.8 %, p ≤ 0.298), (20.0 % Vs 9.4 %, P≤ 0.456) respectively. Table 2 showed these results. 
ALT and AST levels, CD4+ T cell counts and HBe Ag prevalence among study participants with and without HDV infection.
Mean ALT and AST levels were higher and lower respectively among HIV/HBV co-infected participants with and without HDV infection (P˂ 0.940; 0.390 respectively). The mean CD4 + T cells count was lower among HIV/HBV co-infected participants with HDV infection though not statistically significant (P˂ 0.965). All the HBe Ag positivity occurred among HIV/HBV co-infected participants that were not positive for anti HDV 7(21.2 %), however, it was not statistically significant (P˂ 0.570). These results were shown in Table 3 . (Mumtaz et al, 2005) .
The distribution of Delta virus infection was higher among female study participants than in males as well as among study participants that were 41-50 years compared to other age groups, though none was statistically significant. Similarly some studies did not observe association between HDV infection with age and or sex (Motamedifar et al, 2015; Coffie et al, 2017; Ifeorah et al, 2017) . On the contrary, Mumtaz et al, (2005) in their study among HBV infected subjects, observed male gender and younger age to be associated with HDV infection.
The higher prevalence of HDV infection in HIV/HBV co-infected study participants with positive history of multiple sexual partners, needle sharing and blood transfusion even though not statistically significanct, is not unexpected because HBV and HDV infections have common routes (such as sexual and parenteral) of transmission (Greenwood et al, 1997; Sultanik and Pol, 2016) . In contrast, Motamedifar et al, (2015) in their study recorded significant difference with regards to blood transfusion, however did not observe significant difference with regards to intravenous drug usage and unsafe sexual contact. Smaller sample size that were positive for HDV infection may be the reason for not observing statistical difference.
Study participants with tipple infection of HIV/HBV/HDV were observed to have higher mean ALT levels compared to those with HIV/HBV co-infection, though not statistically significant. Similarly, Motamedifar et al, (2015) and Katwesigye et al, (2016) in their studies did not record statistical difference with regards to ALT levels among HIV/HBV co-infected study participants with positive and negative anti HDV. Smaller number of study participants that were positive for anti HDV may probably have contributed to the lack of association. Higher mean ALT levels among Delta virus infected participants compared to non-Delta virus infected participants even though not statistically significant may be a pointer of adverse effect of HDV infection on liver cells and this may result in abnormal ALT levels. On the other hand, mean AST levels was higher among non-HDV infected than in HDV infected HIV/HBV study participants, however it was not statistically significant and this finding is comparable to what Motamedifar et al, (2015) and Katwesigye et al, (2016) documented in similarly related studies. The explanation of this finding in the current study is that, non-Delta virus infected study participants may probably have one or more of other disease conditions such as: myocardial infarction, acute haemolytic anaemia, skeletal muscle disorders and pancreatitis that may also cause AST elevation.
In the current study, HDV infection was observed not have effect on CD4 + T lymphocytes count, though non-HDV reactive among HIV/HBV co-infected study participants had higher mean CD4 + T lymphocytes count. This finding is comparable to what Katwesigye et al, (2016) obtained in their study.
Hepatitis B e antigen is a marker of HBV replication, is implicated in chronic course of HBV infection and its presence makes patient to be highly infectious. However, in the current study, HDV infection was observed not to have effect on HBe Ag expression, as all the HBe Ag positivity occurred among HIV/HBV co-infected study participants that were not positive for anti HDV even though not statistically significant. This may suggest that HDV infection in our study participants may be as a result of super infection and not a co-infection, as ''HDV super-infection may lead to HBe Ag sero-conversion.'' (Sultanik and Pol, 2016) .
